Cyclacel Pharmaceuticals, Inc. (CYCC)
-NasdaqGM 3.04 
0.04(1.33%) May 17, 4:00PM EDT
| Prev Close: | 3.00 |
|---|
| Open: | 3.02 |
|---|
| Bid: | 2.95 x 300 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | 1.73 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 2.99 - 3.07 |
|---|
| 52wk Range: | 2.93 - 8.18 |
|---|
| Volume: | 828,653 |
|---|
| Avg Vol (3m): | 174,749 |
|---|
| Market Cap: | 32.93M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.68 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- CYCLACEL PHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Cyclacel Announces New Stock Issueat Motley Fool(Thu, May 16)
- CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, FinanciaEDGAR Online(Thu, May 16)
- InPlay: Cyclacel Pharma prices offering of 6,666,667 shares of its common stock at $3.00 per shareBriefing.com(Thu, May 16)
- Cyclacel Pharmaceuticals Announces $20 Million Underwritten OfferingGlobeNewswire(Thu, May 16)
- Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common StockGlobeNewswire(Wed, May 15)
- Cyclacel Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Mon, May 13)
- Cyclacel Reports First Quarter 2013 Financial ResultsGlobeNewswire(Mon, May 13)
- CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementEDGAR Online(Mon, May 13)
- Cyclacel Pharmaceuticals to Announce Release of First Quarter 2013 Financial ResultsGlobeNewswire(Fri, May 10)
- Cyclacel Pharmaceuticals' Convertible Exchangeable Preferred Stock Shares Cross 8% Yield Markat Forbes(Mon, May 6)
- Cyclacel Pharmaceuticals update Phase 2 survival data of sapacitabine for MDStheflyonthewall.com(Tue, Apr 30)
- Cyclacel Reports Updated Phase 2 Survival Data of Sapacitabine for MDSGlobeNewswire(Tue, Apr 30)
- A Bullish Argument For Cyclacel's Sapacitabine And Seamlessat Seeking Alpha(Thu, Apr 25)
- Cyclacel Pharmaceuticals to Present at the 12th Annual Needham Healthcare ConferenceGlobeNewswire(Tue, Apr 23)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 470.92 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | N/A |
|---|
| Quarterly EPS Est
(Sep-12)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the development and commercialization of mechanism-targeted drugs to treat human cancers and other serious diseases.
View More